New MRI-guided radiation aims to spare brain tissue in lung cancer patients

NCT ID NCT06582940

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether using MRI-guided adaptive radiotherapy can safely eliminate extra safety margins around brain tumors, potentially reducing radiation-related brain damage. 168 adults with non-small cell lung cancer and 1-10 brain metastases will receive either the new MRI-guided approach or standard radiation. The main goal is to see if the new method lowers the rate of brain necrosis (tissue damage) while still controlling the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-guided adaptive stereotactic radiotherapy
What this could lead to: If successful, this approach could reduce radiation-related brain damage while still controlling brain metastases, improving quality of life for lung cancer patients.
What could go wrong: This is a phase 2 trial with 168 participants, so results are preliminary. The technique is complex and may not work for all patients or may still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer lung neoplasm metastatic malignant neoplasm in the brain non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASIS MRI-GUIDED ADAPTIVE RADIOTHERAPY NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.